Webinar Summary

Efforts to strengthen Europe as a global center for oncology clinical trials have been underway for some time, and multiple initiatives have been launched by stakeholders in recent years.  At the same time, changes at the U.S. FDA and implementation of the EU Health Technology Assessment Regulation from January 2025 are bringing new considerations for sponsors deciding where to place their trial sites.

During this symposium, we will assess what progress has been achieved since the IQVIA Institute’s symposium held a year ago, examine the changes brought by the new U.S. administration, and discuss the impact of Joint Clinical Assessment requirements for all new oncology drugs submitted for registration by the EMA. We will also explore the increased use of trial sites in China and Australia.

In this session, we plan to discuss:

• Progress made over the past year on initiatives to improve Europe’s position as a global center for oncology clinical trials
• Changes in the U.S. affecting oncology research activities and impact on Europe
• Implementation of the European Health Technology Assessment Regulation

The IQVIA Institute will assemble a multi-stakeholder panel to include roles in government, research, pharma, emerging biopharma, CRO, and patient support.

This webinar is open to all, regardless of ESMO membership or affiliation.

This session is ideal for

• Clinical Research & Development Leaders
  
  
  • Heads of Clinical Operations, R&D, and Global Trial Strategy
  • Oncology program leads evaluating trial site selection across regions
• Regulatory & Policy Professionals
  
  
  • EU and U.S. regulatory affairs specialists
  • HTA and market access teams preparing for Joint Clinical Assessment (JCA) requirements
  • Policy analysts tracking FDA and EMA developments
• Pharmaceutical & Biotech Executives
  
  
  • Decision-makers from large pharma and emerging biopharma assessing global trial feasibility
  • Investors and strategists evaluating Europe’s competitiveness in oncology research
• Medical & Scientific Investigators
  
  
  • Principal investigators and site managers from oncology trial centers
  • Academic researchers involved in international trial collaborations
• Clinical Service Providers
  
  
  • CRO professionals focused on protocol design, site selection, and trial execution
  • Data scientists and digital health experts exploring the European Health Data Space and Project Darwin
• Patient Advocacy & Engagement Leaders
  
  
  • Representatives from patient organizations and caregiver networks
  • Stakeholders interested in the patient-centric impact of regulatory and trial site shifts
• Health Policy & Global Affairs Experts
  
  
  • Government and EU representatives involved in life sciences strategy
  • Think tanks and institutes focused on biomedical innovation and international collaboration